Literature DB >> 7592641

Polymerization of microtubule-associated protein tau under near-physiological conditions.

D M Wilson1, L I Binder.   

Abstract

Neurofibrillary tangles, which form in certain degenerating neurons in the brains of patients with Alzheimer's disease, are amassed from filaments having a straight or paired helical morphology. Solubilization of these filaments reveals that they are composed of the microtubule-associated protein tau. It has not previously been shown, however, that tau will assemble to form filaments of similar morphology under conditions representative of the intracellular environment. We have succeeded in forming such filaments using tau purified from porcine or rat microtubules. The filaments are relatively straight with narrowing at irregular intervals, and are about 10 nm wide, a morphology similar to that of straight filaments seen in Alzheimer's disease neurofibrillary tangles. At tau concentrations of 1-10 microM, in vitro assembly occurs at physiological pH, ionic strength, temperature, and reducing potential, and each one of these factors modulates the reaction. Assembly is judged to be only slowly reversible by the exponential rather than normal distribution of filament lengths, and by the limited disassembly observed under conditions which inhibit polymerization. Tau purified directly from whole brain tissue rather than from microtubules does not polymerize under conditions described in this report.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7592641     DOI: 10.1074/jbc.270.41.24306

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  23 in total

1.  Structural analysis of Pick's disease-derived and in vitro-assembled tau filaments.

Authors:  M E King; N Ghoshal; J S Wall; L I Binder; H Ksiezak-Reding
Journal:  Am J Pathol       Date:  2001-04       Impact factor: 4.307

2.  Role of glycosaminoglycans in determining the helicity of paired helical filaments.

Authors:  M Arrasate; M Pérez; J M Valpuesta; J Avila
Journal:  Am J Pathol       Date:  1997-10       Impact factor: 4.307

3.  Effect of human neuronal tau on denaturation and reactivation of rabbit muscle D-glyceraldehyde-3-phosphate dehydrogenase.

Authors:  Y H Chen; R Q He; Y Liu; Y Liu; Z G Xue
Journal:  Biochem J       Date:  2000-10-01       Impact factor: 3.857

Review 4.  Regulated phosphorylation and dephosphorylation of tau protein: effects on microtubule interaction, intracellular trafficking and neurodegeneration.

Authors:  M L Billingsley; R L Kincaid
Journal:  Biochem J       Date:  1997-05-01       Impact factor: 3.857

5.  In vitro aggregation assays using hyperphosphorylated tau protein.

Authors:  Dexin Sui; Mengyu Liu; Min-Hao Kuo
Journal:  J Vis Exp       Date:  2015-01-02       Impact factor: 1.355

6.  Free fatty acids stimulate the polymerization of tau and amyloid beta peptides. In vitro evidence for a common effector of pathogenesis in Alzheimer's disease.

Authors:  D M Wilson; L I Binder
Journal:  Am J Pathol       Date:  1997-06       Impact factor: 4.307

7.  Remodeling of the conformational ensemble of the repeat domain of tau by an aggregation enhancer.

Authors:  Elias Akoury; Marco D Mukrasch; Jacek Biernat; Katharina Tepper; Valery Ozenne; Eckhard Mandelkow; Martin Blackledge; Markus Zweckstetter
Journal:  Protein Sci       Date:  2016-03-24       Impact factor: 6.725

Review 8.  Intrinsically disordered proteins in the neurodegenerative processes: formation of tau protein paired helical filaments and their analysis.

Authors:  Rostislav Skrabana; Jozef Sevcik; Michal Novak
Journal:  Cell Mol Neurobiol       Date:  2006-06-16       Impact factor: 5.046

9.  Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines.

Authors:  C M Wischik; P C Edwards; R Y Lai; M Roth; C R Harrington
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-01       Impact factor: 11.205

Review 10.  Mechanism-based treatments for Alzheimer's disease.

Authors:  Peter Davies; Jeremy Koppel
Journal:  Dialogues Clin Neurosci       Date:  2009       Impact factor: 5.986

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.